Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.55 |
| ▸ | LTA4H | P09960 | 7/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.52 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.49 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.49 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2493839 | 0.85 | LTA4H (0.60) | HRH3LTA4HADORA2AADORA1ADORA2B | |
| SCHEMBL265809 | 0.82 | LTA4H (0.55) | HRH3LTA4HPTGS1PTGS2ADORA2A | |
| SCHEMBL4080135 | 0.78 | LTA4H (0.56) | HRH3LTA4HPTGS1PTGS2PSMB1 | |
| SCHEMBL28997664 | 0.74 | LTA4H (0.55) | HRH3LTA4HPTGS1PTGS2PSMB1 | |
| SCHEMBL11242966 | 0.74 | HRH3 (0.51) | HRH3LTA4HPTGS1PTGS2ADORA2A | |
| SCHEMBL56495 | 0.74 | LTA4H (0.90) | HRH3LTA4HPTGS1PTGS2PSMB1 | |
| SCHEMBL8096602 | 0.73 | NOS3 (0.60) | HRH3LTA4HPTGS1PTGS2ADORA2A | |
| SCHEMBL23724061 | 0.73 | LTA4H (0.87) | HRH3LTA4HPTGS1PTGS2PSMB1 | |
| SCHEMBL3937460 | 0.73 | LTA4H (0.87) | HRH3LTA4HPTGS1PTGS2PSMB1 | |
| Hydrochloric Acid SCHEMBL15254264 | 0.73 | LTA4H (0.87) | HRH3LTA4HPTGS1PTGS2PSMB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | DTYMK, SRC, DCK | HRH3 2085/4885LTA4H 3257/4885PTGS1 2666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.